{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsing+Forms+of+Multiple+Sclerosis&page=2",
    "query": {
      "condition": "Relapsing Forms of Multiple Sclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsing+Forms+of+Multiple+Sclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:26:36.153Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01070836",
      "title": "JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35895,
      "start_date": "2010-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-29",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 473,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucaloosa",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070836"
    },
    {
      "nct_id": "NCT04676555",
      "title": "Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-05-11",
      "completion_date": "2021-10-21",
      "has_results": false,
      "last_update_posted_date": "2022-10-24",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 1,
      "location_summary": "Lutherville, Maryland",
      "locations": [
        {
          "city": "Lutherville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676555"
    },
    {
      "nct_id": "NCT06395909",
      "title": "A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis",
        "Clinically Isolated Syndrome",
        "Relapsing Remitting Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2023-04-23",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06395909"
    },
    {
      "nct_id": "NCT01216072",
      "title": "A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Standard MS DMTs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2010-08",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01216072"
    },
    {
      "nct_id": "NCT06141473",
      "title": "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Frexalimab",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "MRI contrast-enhancing agents",
          "type": "DRUG"
        },
        {
          "name": "Cholestyramine",
          "type": "DRUG"
        },
        {
          "name": "Activated charcoal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1655,
      "start_date": "2023-12-13",
      "completion_date": "2027-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06141473"
    },
    {
      "nct_id": "NCT00418145",
      "title": "Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "megadose oral methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "IV methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Lublin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2003-09",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-05-18",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 10,
      "location_summary": "New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00418145"
    },
    {
      "nct_id": "NCT01201356",
      "title": "Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4125,
      "start_date": "2010-09-13",
      "completion_date": "2018-10-19",
      "has_results": true,
      "last_update_posted_date": "2021-04-21",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 34,
      "location_summary": "Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01201356"
    },
    {
      "nct_id": "NCT00110396",
      "title": "Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon-beta-1a FBS-free/HSA-free",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 260,
      "start_date": "2005-01",
      "completion_date": "2007-04",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110396"
    },
    {
      "nct_id": "NCT01144351",
      "title": "A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ELND002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 17,
      "location_summary": "Berkeley, California • Fresno, California • Newport Beach, California + 14 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144351"
    },
    {
      "nct_id": "NCT01070719",
      "title": "Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Relapse"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "John F. Foley, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 270,
      "start_date": "2010-02",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2012-03-01",
      "last_synced_at": "2026-07-22T16:26:36.153Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070719"
    }
  ]
}